Jefferson Institute for Bioprocessing: Site plan and launch update

By Flora Southey contact

- Last updated on GMT

A rendering of the Jefferson Institute for Bioprocessing at Spring House Innovation Park, Pennsylvania, US
A rendering of the Jefferson Institute for Bioprocessing at Spring House Innovation Park, Pennsylvania, US
The Jefferson Institute for Bioprocessing is set to launch in spring 2019, in Jefferson University’s new Spring House Innovation Park.

Philadelphia’s Jefferson University – the result of a merger between Philadelphia University and Thomas Jefferson University – has announced its bioprocessing institute will open in the first half of 2019.

The 133-acre Spring House Innovation Park campus, located in Lower Gwynedd, Pennsylvania, will house the 25,000 sq. ft. Institute, designed to educate 2,500 people per year, including industry professionals and Jefferson University students.

“Our facility at Spring House Innovation Park will utilise leading-edge biopharmaceutical manufacturing technology and support current and future workforce demands in this critically important field,” ​said associate provost for applied research at Jefferson (Philadelphia University + Thomas Jefferson University) Ron Kander in a statement.

The Jefferson Institute for Bioprocessing was first announced in partnership with Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) in February this year​.

At the time, NIBRT CEO Dominic Carolan said the new Institute responds to an increased demand for biologic drugs: “There is a significant demand for global talent to support the growth of the biopharmaceutical manufacturing industry and our relationship with Jefferson will help address this demand throughout the United States.”

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars